ArticleOxford medical case reports2026
Diagnosis and management of Brugada Syndrome Unmasked by Flecainide challenge in a patient with unexplained ventricular fibrillation: a case report.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Brugada syndrome is a genetic disorder associated with sudden cardiac death (SCD) due to ventricular fibrillation (VF). The diagnosis relies on detecting a Type 1 ST-segment elevation in the right precordial leads, which often requires sodium channel blocker provocation for confirmation. Patient concerns: We present a case of a 55-year-old male bus driver who experienced out-of-hospital cardiac arrest due to VF. Diagnosis: After resuscitation, initial evaluations, including echocardiography and cardiac enzyme tests, were normal, showing no structural heart disease. The initial electrocardiogram displayed a Type 2 Brugada pattern. Intervention: A flecainide challenge test using oral flecainide (300 mg) revealed a Type 1 Brugada pattern, confirming Brugada syndrome. Outcomes: Despite mild hypokalemia, an implantable cardioverter defibrillator (ICD) was implanted due to the patient's high-risk occupation and VF history. Conclusion: This case underscores the importance of considering Brugada syndrome in unexplained VF cases and highlights the role of flecainide testing in diagnosis. A multidisciplinary approach, including thorough evaluation, timely ICD implantation, and patient education, is crucial for optimal outcomes, particularly for those in safety-critical professions. Recognizing Brugada syndrome and applying appropriate diagnostic and therapeutic measures are essential for preventing fatal arrhythmic events. Learning points: This case underscores the importance of considering Brugada syndrome in patients with unexplained ventricular fibrillation, emphasizing the utility of the flecainide challenge test for accurate diagnosis when characteristic ECG findings are not evident.A multidisciplinary approach, including timely diagnosis, appropriate ICD implantation, and patient education, is critical in managing high-risk occupations to prevent catastrophic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.